{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.6.1', 'Discussion of Study Design and Choice of Control Groups', '74', '5.6.2', 'Appropriateness of Measurements', '74', '5.6.3', 'Suitability of Subject Population', '75', '5.6.4', 'Selection of Doses in the Study', '75', '6.0', 'Complaints', '75', '6.1', 'Medical Complaints', '76', '6.1.1', 'Definitions', '76', '6.1.1.1', 'Adverse Event', '76', '6.1.1.2', 'Serious Adverse Events', '77', '6.1.1.3', 'Adverse Events Expected Due to SCLC or Progression of SCLC', '78', '6.1.2', 'Adverse Event Severity', '79', '6.1.3', 'Relationship to Study Drug', '79', '6.1.4', 'Deaths', '80', '6.1.5', 'Adverse Event Collection Period', '81', '6.1.6', 'Adverse Event Reporting', '82', '6.1.7', 'Pregnancy', '84', '6.1.8', 'Toxicity Management', '84', '6.1.8.1', 'Management of Serosal Effusions/Serositis', '85', '6.1.8.2', 'Management of Skin Reactions', '85', '6.1.8.3', 'Management of Potential Drug-Induced Liver Injury', '87', '6.1.8.4', 'Monitoring and Management of Edema', '89', '6.1.8.5', 'Pneumonitis', '91', '6.2', 'Product Complaint', '92', '6.2.1', 'Definition', '92', '6.2.2', 'Reporting', '92', '7.0', 'Protocol Deviations', '93', '8.0', 'Statistical Methods and Determination of Sample', 'Size', '94', '8.1', 'Statistical and Analytical Plans', '94', '8.1.1', 'Disposition of Study Subjects', '95', '8.1.2', 'Demographics and Baseline Characteristics', '95', '8.1.3', 'Efficacy Endpoints and Analyses', '95', '8.1.4', 'Primary Efficacy Endpoints', '96', '23']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.1.5', 'Secondary Efficacy Endpoints', '97', '8.1.6', 'Exploratory Efficacy Endpoints', '97', '8.1.7', 'Patient Reported Outcomes (PRO)', '98', '8.1.8', 'Planned Sensitivity and Subgroup Analyses', '99', '8.1.9', 'Pharmacokinetic and Exposure-Response Analyses', '99', '8.2', 'Safety Analyses', '100', '8.2.1', 'Treatment-Emergent Adverse Events (TEAEs)', '100', '8.2.2', 'Clinical Laboratory Evaluation', '101', '8.2.3', 'Vital Signs', '101', '8.2.4', 'ECOG Performance Status', '101', '8.2.5', 'Electrocardiogram', '101', '8.2.6', 'Concomitant Medications', '101', '8.3', 'Type I Error Adjustment Procedure for Multiple Testing', '101', '8.4', 'Determination of Sample Size', '105', '8.5', 'Futility Analysis', '106', '8.6', 'Accrual/Study Duration Considerations', '106', '8.7', 'Randomization Methods', '107', '9.0', 'Ethics', '107', '9.1', 'Independent Ethics Committee (IEC) or Institutional Review', 'Board (IRB)', '107', '9.2', 'Ethical Conduct of the Study', '108', '9.3', 'Subject Information and Consent', '108', '9.3.1', 'Informed Consent Form and Explanatory Material', '109', '9.3.2', 'Revision of the Consent Form and Explanatory Material', '109', '10.0', 'Source Documents and Case Report Form', 'Completion', '110', '10.1', 'Source Documents', '110', '10.2', 'Case Report Forms', '110', '11.0', 'Data Quality Assurance', '112', '12.0', 'Use of Information', '112', '13.0', 'Completion of the Study', '113', '14.0', \"Investigator's Agreement\", '114', '15.0', 'Reference List', '115', '24']\n\n###\n\n", "completion": "END"}